ALS News Today3h
New ALS trial data show nearly 2-year survival benefit with NP001
A 22-month survival benefit was seen for a subset of ALS patients whose disease did not progress when treated with NP001 in ...
PharmaTimes4h
Vedanta Biosciences reveals Phase 2 VE303 results
Vedanta Biosciences has published additional results from its Phase 2 CONSORTIUM study for VE303, a potential first-in-class ...
NanoViricides Engages CRO for Phase II Clinical Trial
NanoViricides, Inc. (NYSE American:NNVC) (the “Company”) today announced that it has engaged a Clinical Research Organization (CRO) to conduct a Phase II clinical trial advancing its broad-spectrum ...
News Medical12h
Real-world data reveals survival benefits of anatomic resections for early-stage lung cancer
New research presented at the 2025 Society of Thoracic Surgeons (STS) Annual Meeting reveals that anatomic lung resections, such as lobectomy and segmentectomy, are associated with improved long-term ...
BioArctic: FDA approves IV maintenance dosing of Leqembi (lecanemab-irmb) for the treatment of early Alzheimer's Disease in the US
BioArctic AB (publ) (NASDAQ STOCKHOLM: BIOA B) today announced that the U.S. Food and Drug Administration (FDA) has approved BioArctic's partner Eisai's ...
Biogen Inc.: FDA Approves LEQEMBI (lecanemab-irmb) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease
Once every four weeks maintenance dosing may be easier for patients and care partners to continue treatment Alzheimer's disease progression does not stop after plaque clearance; ongoing treatment with ...